Journal
CURRENT CANCER DRUG TARGETS
Volume 14, Issue 3, Pages 294-309Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568009614666140305222328
Keywords
Breast cancer; chemokine; CXCL3; migration; proteomics; secretome
Categories
Funding
- National University of Singapore (NUS)
- CBRG grant - National Medical Research Council, Ministry of Health, Singapore
Ask authors/readers for more resources
Secreted proteins are an attractive minefield for cancer drug targets. An iTRAQ-based tandem mass spectrometry approach was employed to relatively quantify proteins in the secretomes of four isogenic breast cancer cell lines with increasing metastatic potential. CXCL3 was found to be upregulated in aggressive cancer cells. SiRNA and antibody neutralization studies supported a role of CXCL3 in metastatic processes. Meta-analysis of the mRNA level of CXCL3 in 1881 breast tumors supported a role of CXCL3 in clinical breast cancer. Our results support a functional role of CXCL3 in breast cancer metastasis and as a viable target for cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available